Immunological Reprogramming of Renal Fibrosis: cGAS-STING Axis and Macrophage Polarization Regulation
##1. Renal Fibrosis: Irreversible Barrier in Chronic Kidney Disease Renal fibrosis, the final common pathway of chronic kidney disease (CKD), is an irreversible process that destroys the functional units of the kidney and leads to excessive accumulation of connective tissue. Conventional anti‑inflammatory agents have shown limited ability to reverse or halt already established fibrosis, creating a strong clinical demand to identify the fundamental molecular switches driving the disease.
##2. cGAS‑STING Pathway: Molecular Controller of Macrophage Induction Recent studies have revealed that the innate immune sensor cGAS‑STING pathway plays a pivotal role in determining macrophage phenotype. When cGAS detects DNA released from injured renal cells and activates STING, macrophages shift to a potent pro‑inflammatory (M1) state. The interferons and cytokines released in this process stimulate myofibroblasts, driving excessive extracellular matrix (ECM) production and acting as an engine that accelerates fibrosis.
##3. Multifaceted Inhibition Strategies: From Small Molecules to Gene Editing Innovative approaches to block the cGAS‑STING axis are achieving encouraging results in preclinical models. Small‑molecule inhibitors directly block STING activity, re‑programming macrophages toward an anti‑inflammatory (M2) phenotype. Nanoparticle‑based delivery systems enable precise targeting of therapeutics to injured renal sites, dramatically reducing systemic side effects. Moreover, CRISPR‑based gene‑editing technologies add a layer of precision medicine by disrupting fibrotic signaling at its source.
##4. A New Paradigm for CKD Management and Clinical Expectations If translated into clinical practice, this research could provide CKD patients with disease‑modifying therapy that not only alleviates symptoms but also suppresses fibrosis progression. Restoring immune balance in macrophages may delay the transition to end‑stage renal disease and lower dependence on dialysis, representing a decisive key. Should the efficiency of targeted delivery and long‑term safety be validated, a paradigm shift in the renal disease therapeutic market is anticipated.
Renal fibrosis, a pivotal pathological hallmark of chronic kidney disease (CKD), arises from persistent inflammatory responses and extracellular matrix (ECM) deposition. Emerging evidence indicates the cyclic GMP-AMP synthase-stimulator of interferon genes (cGAS-STING) signaling pathway exerts a crucial influence on the progression of renal fibrosis. This pathway exacerbates the release of inflammatory factors and ECM deposition through reprogramming the polarization state of macrophages, thereby driving renal fibrosis. This review delineates the regulatory role of the cGAS-STING signaling pathway in macrophage-related renal fibrosis and critically evaluates emerging innovative strategies targeting this pathway, including small molecule inhibitors, nanocarrier-based delivery systems, and gene editing technologies. However, current research still faces certain limitations, including the complexity of molecular mechanisms, differences in research results, and challenges in clinical translation. By synthesizing recent advances in cGAS-STING-mediated macrophage reprogramming for renal fibrosis intervention, this review aims to provide a foundation for precise therapeutic development.
Renal fibrosis is a concrete problem that markedly worsens renal function and increases the risk of dialysis and transplantation in CKD patients. Precisely blocking the cGAS‑STING‑macrophage axis can prevent the decline in quality of life associated with kidney disease in everyday life.